For the year ending 2025-12-31, PTGX made $46,016K in revenue. -$130,149K in net income. Net profit margin of -282.83%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| License and collaboration revenue | 46,016 | |||
| Research and development | 159,290 | |||
| General and administrative | 44,853 | |||
| Total operating expenses | 204,143 | |||
| (loss) income from operations | -158,127 | |||
| Interest income | 28,789 | |||
| Other income (expense), net | 27 | |||
| (loss) income before income tax expense | -129,311 | |||
| Provision for income taxes | 838 | |||
| Net (loss) income | -130,149 | |||
| Basic EPS | -2.05 | |||
| Diluted EPS | -2.05 | |||
| Basic Average Shares | 63,573,048 | |||
| Diluted Average Shares | 63,573,048 | |||
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)